NCT05558644 Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET)
| NCT ID | NCT05558644 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Curie |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-08-03 |
| Primary Completion | 2026-10-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-08-03 with a primary completion date of 2026-10-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).
Eligibility Criteria
Inclusion Criteria: 1. Patient with suspicion of localised thymic epithelial tumour. 2. Age ≥ 18 years. 3. Treatment-naïve patient for this disease. 4. Patient with an indication for thymectomy and thymomectomy in one of the partner centers. 5. Signed informed consent form of the patient. Exclusion Criteria: 1. Neoadjuvant chemotherapy. 2. No social security affiliation. 3. Person under legal protection. 4. Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).
Contact & Investigator
Clémence BASSE, MD
STUDY DIRECTOR
Institut Curie Paris
Frequently Asked Questions
Who can join the NCT05558644 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05558644 currently recruiting?
Yes, NCT05558644 is actively recruiting participants. Contact the research team at clemence.basse@curie.fr for enrollment information.
Where is the NCT05558644 trial being conducted?
This trial is being conducted at Paris, France, Paris, France, Suresnes, France.
Who is sponsoring the NCT05558644 clinical trial?
NCT05558644 is sponsored by Institut Curie. The principal investigator is Clémence BASSE, MD at Institut Curie Paris. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.